Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890218111> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2890218111 abstract "e14033 Background: The MetAction project consists of two clinical trial phases. The completed first phase established the required diagnostic infrastructure, implemented security-approved systems for handling of sensitive information, educated the entire project staff within the context of tumor boards, and estimated costs of the initiative within public health services. The endeavor enabled expedite and safe mutation profiling of metastatic tumors in order to offer biomarker-based treatment with molecularly matched medication to patients with end-stage cancer, as reported in Ree et al., ESMO Open 2017. The ongoing second trial phase investigates the feasibility of the established MetAction pipeline in clinical practice. Methods: An eligible patient has end-stage metastatic disease from a solid cancer. Metastatic tissue is analyzed by DNA sequencing (Ion Oncomine™ Comprehensive Panel), where called variants are filtered prior to assessment and prioritization, supplemented with fluorescence in situ hybridization to cover relevant biomarkers. The Molecular Tumor Board interprets the findings within the likelihood of signaling pathway activity, and the sequential Clinical Tumor Board (CTB) may conclude on treatment with any systemic tumor-directed medication. Results: At the time of writing, 19 patients enrolled onto the second trial phase have accomplished the diagnostic procedures from sampling of metastatic tissue to CTB conclusion. Biopsy procedures were undertaken at lung or pleural sites (five cases), liver or superficial or deep peritoneal sites (13 cases), and an inguinal lymph node (one case) and did not cause adverse events. Histologic entities were 12 adenocarcinomas and one case each of squamous cell and undifferentiated carcinoma, cholangiocarcinoma, and four different sarcoma entities. Twelve patients have been found eligible for off-label use of molecularly matched therapy (inhibitor of ALK-, BRAF-, EGFR-, FGFR-, mTOR-, PARP-, or PD-1-mediated signaling). Conclusions: We will report on patient outcome (progression-free survival, overall response rate, and tolerance) to this biomarker-directed treatment in end-stage cancer. Clinical trial information: NCT02142036." @default.
- W2890218111 created "2018-09-27" @default.
- W2890218111 creator A5000454733 @default.
- W2890218111 creator A5007823953 @default.
- W2890218111 creator A5011277446 @default.
- W2890218111 creator A5011623279 @default.
- W2890218111 creator A5021161507 @default.
- W2890218111 creator A5031803655 @default.
- W2890218111 creator A5032336324 @default.
- W2890218111 creator A5033220044 @default.
- W2890218111 creator A5038023987 @default.
- W2890218111 creator A5041567552 @default.
- W2890218111 creator A5043846022 @default.
- W2890218111 creator A5044318565 @default.
- W2890218111 creator A5045788796 @default.
- W2890218111 creator A5053482931 @default.
- W2890218111 creator A5056318188 @default.
- W2890218111 creator A5063781924 @default.
- W2890218111 creator A5074133414 @default.
- W2890218111 creator A5076275499 @default.
- W2890218111 creator A5077983744 @default.
- W2890218111 creator A5088846853 @default.
- W2890218111 date "2017-05-20" @default.
- W2890218111 modified "2023-09-24" @default.
- W2890218111 title "The MetAction project: Biomarker-directed molecularly matched therapy for end-stage cancer implemented in clinical practice." @default.
- W2890218111 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e14033" @default.
- W2890218111 hasPublicationYear "2017" @default.
- W2890218111 type Work @default.
- W2890218111 sameAs 2890218111 @default.
- W2890218111 citedByCount "0" @default.
- W2890218111 crossrefType "journal-article" @default.
- W2890218111 hasAuthorship W2890218111A5000454733 @default.
- W2890218111 hasAuthorship W2890218111A5007823953 @default.
- W2890218111 hasAuthorship W2890218111A5011277446 @default.
- W2890218111 hasAuthorship W2890218111A5011623279 @default.
- W2890218111 hasAuthorship W2890218111A5021161507 @default.
- W2890218111 hasAuthorship W2890218111A5031803655 @default.
- W2890218111 hasAuthorship W2890218111A5032336324 @default.
- W2890218111 hasAuthorship W2890218111A5033220044 @default.
- W2890218111 hasAuthorship W2890218111A5038023987 @default.
- W2890218111 hasAuthorship W2890218111A5041567552 @default.
- W2890218111 hasAuthorship W2890218111A5043846022 @default.
- W2890218111 hasAuthorship W2890218111A5044318565 @default.
- W2890218111 hasAuthorship W2890218111A5045788796 @default.
- W2890218111 hasAuthorship W2890218111A5053482931 @default.
- W2890218111 hasAuthorship W2890218111A5056318188 @default.
- W2890218111 hasAuthorship W2890218111A5063781924 @default.
- W2890218111 hasAuthorship W2890218111A5074133414 @default.
- W2890218111 hasAuthorship W2890218111A5076275499 @default.
- W2890218111 hasAuthorship W2890218111A5077983744 @default.
- W2890218111 hasAuthorship W2890218111A5088846853 @default.
- W2890218111 hasConcept C121608353 @default.
- W2890218111 hasConcept C126322002 @default.
- W2890218111 hasConcept C143998085 @default.
- W2890218111 hasConcept C185592680 @default.
- W2890218111 hasConcept C2781197716 @default.
- W2890218111 hasConcept C55493867 @default.
- W2890218111 hasConcept C71924100 @default.
- W2890218111 hasConceptScore W2890218111C121608353 @default.
- W2890218111 hasConceptScore W2890218111C126322002 @default.
- W2890218111 hasConceptScore W2890218111C143998085 @default.
- W2890218111 hasConceptScore W2890218111C185592680 @default.
- W2890218111 hasConceptScore W2890218111C2781197716 @default.
- W2890218111 hasConceptScore W2890218111C55493867 @default.
- W2890218111 hasConceptScore W2890218111C71924100 @default.
- W2890218111 hasLocation W28902181111 @default.
- W2890218111 hasOpenAccess W2890218111 @default.
- W2890218111 hasPrimaryLocation W28902181111 @default.
- W2890218111 hasRelatedWork W1527749645 @default.
- W2890218111 hasRelatedWork W1559592205 @default.
- W2890218111 hasRelatedWork W2307669640 @default.
- W2890218111 hasRelatedWork W2320260494 @default.
- W2890218111 hasRelatedWork W2328344944 @default.
- W2890218111 hasRelatedWork W2559871367 @default.
- W2890218111 hasRelatedWork W2832093183 @default.
- W2890218111 hasRelatedWork W2890414536 @default.
- W2890218111 hasRelatedWork W2890888336 @default.
- W2890218111 hasRelatedWork W2953263748 @default.
- W2890218111 hasRelatedWork W2978514052 @default.
- W2890218111 hasRelatedWork W3029072894 @default.
- W2890218111 hasRelatedWork W3102412870 @default.
- W2890218111 isParatext "false" @default.
- W2890218111 isRetracted "false" @default.
- W2890218111 magId "2890218111" @default.
- W2890218111 workType "article" @default.